Enterprise Value

-17.57M

Cash

32.17M

Avg Qtr Burn

-6.494M

Short % of Float

0.28%

Insider Ownership

3.23%

Institutional Own.

10.23%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Annamycin Details
Soft tissue sarcoma, Solid tumor/s, Cancer, Lung Metastases, Sarcoma

Phase 1/2

Data readout

Annamycin + Ara-C Details
Blood cancer, Cancer, Acute myeloid leukemia

Phase 1/2

Data readout

WP1066 (p-STAT3 inhibitor) Details
Brain tumor, Solid tumor/s, Cancer, Glioblastoma

Phase 1/2

Initiation

WP1066 (p-STAT3 inhibitor) Details
Cancer, Brain tumor, Solid tumor/s, Glioma

Phase 1

Data readout

WP1220 Details
Cutaneous T cell lymphoma, Blood cancer, Cancer, T-cell lymphoma

Failed

Discontinued

Failed

Discontinued